New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2012
22:26 EDTCRM, HBI, PVH, JNJ, EOG, ZAGG, RRD, RL, FUN, AAPL, NFLX, REGN, VFC, HD, AEP, WMJim Cramer's "Mad Money"
Jim Cramer said, "Once people feel stocks aren't the enemy, we'll head higher". He pondered the significance of the Dow hitting 13,000- and said "this milestone matters". Professional investors tend to focus on the S&P 500, but for smaller investors, retail investors, Dow 13,000 could be significant. Breaking 13,000 could be just want the little guys need to jump back in, Cramer says. Long-term, stocks are still the best game in town when compared to bonds, U.S. treasuries and bank CDs, he noted. Cramer remained bullish on high-yielding dividend stocks, names like Cedar Fair (FUN) and American Electric Power (AEP), especially given that dividends receive special tax treatments. EXECUTIVE DECISION: Cramer spoke with Mark Papa, chairman and CEO of EOG Resources (EOG), which delivered a 28c earnings beat on a 55% rise in revenues last week. Shares of EOG are currently trading below where it reported those stellar numbers. Papa said that despite what Wall Street thinks, he's very comfortable with the company's game plan and will continue to reduce natural gas production and ramp up oil and liquids production until natural gas prices stabilize. His outlook on oil prices however, remained strong. Papa estimated the price of oil to be between $100-$110 a barrel, barring a conflict in Iran, based simply on rising worldwide demand. Cramer remained bullish on EOG, telling investors that the company is still one of his favorite oil plays. OFF THE CHARTS: Cramer and colleague Dan Fitzpatrick went over the chart of Apple (AAPL). Fitzpatrick said the rally appears done, for now, until all of the momentum players get flushed out of the stock. Fitzpatrick's only caveat, if Apple were to break through its highs of $526 a share, then the stock would be poised for still another move higher. Cramer said he doesn't care about the charts when it comes to Apple. He said that earnings power is all that matters for this tech juggernaut. With the company elected to earn upwards of $55 a share in earnings, Cramer said he would step up and buy Apple on any weakness. Next, Cramer once again welcomed David Steiner, president and CEO of Waste Management (WM), to the show for an update on the company's outlook. Steiner said that Waste Management is seeing a steady recovery in trash volumes, a trend he expects to see continue throughout 2012. Cramer gave kudos to Steiner for the company's near 4% dividend yield and reiterated his buy recommendation on the the stock. NO HUDDLE OFFENSE: Gas prices are clearly hinged on the building conflict with Iran. Cramer said that gas prices won't likely go lower until the conflict is resolved or the world economy slows to where demand for gasoline falls dramatically. CLOSING COMMENTS: Cramer removed outgoing Johnson & Johnson (JNJ) CEO, William Weldon, from his Wall of Shame list of the worst CEO's. He said that after so many product recalls under Weldon's tenure, wealth will have to be created for J&J shareholders now that he's retiring. Cramer also had bullish words for Home Depot (HD), which reported a strong quarter Tuesday. LIGHTNING ROUND: (Bullish) RL; PVH; VFC. (Bearish) RRD; HBI; REGN; ZAGG; CRM; NFLX. Reference Link
News For WM;AAPL;EOG;AEP;FUN;JNJ;HD;RL;PVH;VFC;RRD;HBI;REGN;ZAGG;CRM;NFLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
December 9, 2014
09:21 EDTAAPLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: AutoZone (AZO), up 3.8%... Burlington Stores (BURL), up 3.3%. ALSO HIGHER: bluebird bio (BLUE), up 56.5% after price target raised at Piper Jaffray and SunTrust... Camtek (CAMT), up 6.7% after being awarded a $2.8M order from a semiconductor manufacturer... PDC Energy (PDCE), up 5.8% after providing fiscal 2015 production guidance... Mast Therapeutics (MSTX), up 3.1% after reporting that it will begin recruiting patients for MST-188 study in first half of fiscal 2015... Idera Pharmaceuticals (IDRA), up 1.4% after announcing data for its lead product candidate, IMO-8400. DOWN AFTER EARNINGS: UTi Worldwide (UTIW), down 10.8%... CONN'S (CONN), down 35.9% after reporting third quarter results, withdrawing fiscal 2015 guidance, stating that there is no timetable set for completion of strategic alternatives, and announcing the departure of its CFO. ALSO LOWER: Apple (AAPL), down 1.6% after Pacific Crest says that weak iPad demand could cause Apple to miss estimates and following a Wall Street Journal report that a judge denied Apple's efforts to throw out iPod pricing lawsuit... Allied Nevada Gold (ANV), down 30.1% after announcing pricing of common stock and warrant offering... United Continental (UAL), down 2.7% after reporting November traffic.
08:03 EDTAAPLWeak iPad demand could cause Apple to miss estimates, says Pacific Crest
Subscribe for More Information
07:01 EDTEOGEOG Resources coverage resumed with a Hold at Stifel
06:48 EDTNFLXNetflix wants to be 'completely global' within five years, GigaOM reports
Netflix Chief Content Officer Ted Sarandos told investors at the UBS Global Media and Communications Conference that the company wants to be "completely global" and available everywhere in the world before 2020, GigaOM reports. CEO Reed Hastings has previously said that the company could eventually generate up to 80% of its revenue outside the U.S. Reference Link
06:20 EDTAAPLJudge denies Apple's efforts to throw out iPod pricing suit, WSJ reports
Subscribe for More Information
06:00 EDTCRMSalesforce.com names YouTube CEO Susan Wojcicki to board
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
18:37 EDTEOGEOG Resources divests majority of Canadian assets
EOG Resources announced the divestiture of all its assets in Manitoba and certain assets in Alberta in two separate transactions that closed on November 28 and December 1. Approximate proceeds from the divestitures were US$410M, net of customary transaction adjustments. As a result of these transactions, approximately US$150M of restricted cash related to future abandonment liabilities was released. The proceeds and cash will be utilized for general corporate purposes. Current forecast production from the divested assets is approximately 7,050 barrels of crude oil per day, 580 barrels of natural gas liquids per day and 43.5M cubic feet of natural gas per day. Net proved reserves divested are estimated to be 7.7M barrels of oil, 0.8M barrels of NGLs and 78.7B cubic feet of natural gas. EOG divested 1.3M gross acres, 97% of which were in Alberta. Of the approximate 5,800 producing wells sold, 5,255 were natural gas. EOG has retained approximately 382,200 gross acres in Alberta, British Columbia and Saskatchewan. EOG will maintain an operations office in Alberta
16:00 EDTAAPLOptions Update; December 8, 2014
Subscribe for More Information
13:16 EDTAAPLApple trades off session lows, levels to watch
Subscribe for More Information
11:29 EDTNFLXNetflix falls to session lows, levels to watch
The shares are down over 2% to $342.44. At that price next support is at $340.05. Resistance is at $345.45.
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:12 EDTVFCVF Corp., IFC distribute financing to Bangladeshi factories
VF Corporation and IFC, a member of the World Bank Group, announced they have provided loans to three Bangladeshi garment factories under a new program for funding fire and building safety improvements. Through the financing arrangement, VF provides a full corporate guarantee for up to $10M that the IFC and its partner BRAC Bank lend to VFs contract suppliers. VFs guarantee to back the loans makes it possible for IFC to lend at lower interest rates. This initiative helps VF suppliers in Bangladesh overcome financial obstacles to improving workplace safety conditions.
07:28 EDTCRMFBN Securities to hold a bus tour
Subscribe for More Information
06:37 EDTAAPLApple rumored to be launching 4-inch iPhone in 2015, Times of India reports
Apple is rumored to be developing a new iPhone with a 4-inch display, The Times of India reports, citing a report from The Electronic Times of Taiwan. According to supply chain sources, the device will launch in 2H15. Reference Link
06:22 EDTAAPLApple price target raised to $135 from $120 at Citigroup
Citigroup raised its earnings estimates for Apple after its field work indicated consumers are increasingly buying the higher memory iPhone 6 and 6+. Citi expects purchasing trends towards higher memory devices to drive stronger sales and margins. It believes consensus estimates are yet to factor in this development. The firm raised its price target for Apple shares to $135 from $120 and keeps a Buy rating on the name. Shares of phone maker closed Friday down 49c to $115.
06:15 EDTAAPLLenovo shipments expected to lead Samsung by 9M in 2015, DigiTimes reports
Lenovo (LNVGY) is estimated to beat Samsung (SSNLF) in mobile device shipments in 2015 by about 9M units, reports DigiTimes Research. Lenovo is set to beat Samsung by about 1M units in 2014 and become the second largest mobile computing device brand vendor worldwide behind Apple (AAPL). DigiTimes Research says Lenovo and Samsung plan to focus on maintaining tablet shipments as demand weakens in 2015. Reference Link
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use